Skip to main content
NCBI home page
Springer Nature - PMC COVID-19 Collection logoLink to Springer Nature - PMC COVID-19 Collection
. 2009 Apr 16;52(4):415–458. doi: 10.1007/s11426-009-0103-2

Review on supermolecules as chemical drugs

ChengHe Zhou 1,✉, LinLing Gan 2, YiYi Zhang 1, FeiFei Zhang 1, GuangZhou Wang 1, Lei Jin 2, RongXia Geng 1
PMCID: PMC7089408  PMID: 38624300

Abstract

Supramolecular medicinal chemistry field has been a quite rapidly developing, increasingly active and newly rising interdiscipline which is the new expansion of supramolecular chemistry in pharmaceutical sciences, and is gradually becoming a relatively independent scientific area. Supramolecular drugs could be defined as medicinal supermolecules formed by two or more molecules through non-covalent bonds. So far a lot of supermolecules as chemical drugs have been widely used in clinics. Supermolecules as chemical drugs, i.e. supramolecular chemical drugs or supramolecular drugs, which might have the excellences of lower cost, shorter period, higher potential as clinical drugs for their successful research and development, may possess higher bioavailability, better biocompatibility and drug-targeting, fewer multidrug-resistances, lower toxicity, less adverse effect, and better curative effects as well as safety, and therefore exhibit wide potential application. These overwhelming advantages have drawn enormous special attention. This paper gives the definition of supramolecular drugs, proposes the concept of supramolecular chemical drugs, and systematically reviews the recent advances in the research and development of supermolecules, including organic and inorganic complex ones as chemical drugs in the area of antitumor, anti-inflammatory, analgesic, antimalarial, antibacterial, antifungal, antivirus, anti-epileptic, cardiovascular agents and magnetic resonance imaging agents and so on. The perspectives of the foreseeable future and potential application of supramolecules as chemical drugs are also presented.

Keywords: supramolecular chemistry, cyclodextrin, porphyrin, complex, anticancer, anti-inflammatory, antibacterial, antifungal, antivirus, cardiovascular agent, magnetic resonance imaging agent, supramolecular drug

Footnotes

Supported by the Southwest University (Grant Nos. SWUB2006018 & XSGX0602), the Natural Science Foundation of Chongqing (Grant Nos. 2007BB5369 & 2006BB4341) and the Key Project from the Personnel Department of China (Grant No. 2002-99)

References

  • 1.Lehn J. M. Supramolecular Chemistry-Concepts and Perspectives. Weinheim: VCH; 1995. [Google Scholar]
  • 2.Lehn J. M., Atwood J. L., Davies L. E. D., MacNIcol D. D., Vögtle F. Comprehensive Supramolecular Chemistry. New York: Pergamon; 1996. [Google Scholar]
  • 3.Liu Y., You C. C., Zhang H. Y. Supramolecular Chemistry-Molecular Recognition and Assembly of Synthesized Receptors. Tianjin: Nankai University Press; 2001. [Google Scholar]
  • 4.Steed J. W., Atwood J. L. Supramolecular Chemistry. Chichester: John Wiley & Sons; 2000. [Google Scholar]
  • 5.Dodziuk H. Introduction to Supramolecular Chemistry. Dordrecht: Kluwer Academic Publishers; 2002. [Google Scholar]
  • 6.Zhang X., Lin Z. H., Gao Q., Vögtle F., editors. Supramolecular Chemisty. Jilin: Jilin University Press; 1995. [Google Scholar]
  • 7.Tong L. H., Shen B. J. Physical Methods in Supramolecular Chemistry. Beijing: Science Press; 2004. [Google Scholar]
  • 8.Sun X. Q., Meng Q., Yan H. B. Introduction of Supramolecular Chemisty. Beijing: China Petrochemical Press; 2000. [Google Scholar]
  • 9.Bianchi A., Bowman-James K., Garcia-Espana E. Supramolecular Chemistry of Anions. New York: John Wiley & Sons; 1997. [Google Scholar]
  • 10.Yui N. Supramolecular Design for Biological Applications. Boca Raton: CRC Press; 2002. [Google Scholar]
  • 11.Jones W., Rao C. N. R. Supramolecular Organization and Materials Design. Cambridge: Cambridge University Press; 2002. [Google Scholar]
  • 12.Schneider H. J., Yatsimirsky A. K. Principles and Methods in Supramolecular Chemistry. Chichester: John Wiley & Sons; 2000. [Google Scholar]
  • 13.Shen J. C., Sun J. Q. Research development of supramolacular science. Bull Chin Aca Sci. 2004;19(6):420–424. [Google Scholar]
  • 14.Bertini I., Sigel A., Sigel H. Handbook of Metalloproteins. New York: Marcel Dekker; 2001. [Google Scholar]
  • 15.Li W. Biological Supramolecular Systems (in Chinese) Beijing: Chemical Industry Press; 2003. [Google Scholar]
  • 16.Penadés S. Host-Guest Chemistry-Mimetic Approaches to Study Carbohydrate Recognition. Berlin: Springer; 2002. [Google Scholar]
  • 17.Cho S. K. Synthetic Multivalent Molecules-Concepts and Biomedical Applications. New Jersey: John Wiley & Sons; 2004. [Google Scholar]
  • 18.Wu C. T. Crown Ether Chemistry (in Chinese) Beijing: Science Press; 1992. [Google Scholar]
  • 19.Gloe K. Macrocyclic Chemistry-Current Trends and Future Perspectives. Berlin: Springer; 2005. [Google Scholar]
  • 20.Simons C. Nucleoside Mimetics-Their Chemistry and Biological Properties. Australia: Gordon and Breach Science Publishers; 2001. [Google Scholar]
  • 21.Yang M. Molecular Recognition in the Drug Research (in Chinese) Beijing: Beijing Medical University-Peking Union Medical College Union Press; 1999. [Google Scholar]
  • 22.Li R. X., Yang J. J. Molecular Bionics and Their Application (in Chinese) Beijing: Chemical Industry Press; 2003. [Google Scholar]
  • 23.Yan J. M., Zhou C. H., Xie R. G. Advance in the artificial receptors and enzymes of cyclophane. Chin J Org Chem (in Chinese) 1995;15(6):577–586. [Google Scholar]
  • 24.Luo M. M., Guo J. S., Zhou C. H., Xie R. G. Design and synthesis of imidazolium cyclophane. Heterocycles. 1995;41(7):1421–1424. doi: 10.3987/COM-94-7019. [DOI] [Google Scholar]
  • 25.Zhou C. H., Xie R. G., Zhao H. M. Convenient and efficient synthesis of imidazolium cyclophanes. Org Prep Proc Int. 1996;28(3):345–347. doi: 10.1080/00304949609356541. [DOI] [Google Scholar]
  • 26.Liu Z. C., Zhou C. H., Su X. Y., Xie R. G. First synthesis of estrogen-imidazolium cyclophanes. Synth Commun. 1999;29(17):2979–2983. doi: 10.1080/00397919908086472. [DOI] [Google Scholar]
  • 27.Jiang H. Y., Zhou C. H., Luo K., Chen H., Lan J. B., Xie R. G. Chiral imidazole metalloenzyme models: Synthesis and enantioselective hydrolysis for α-amino acid esters. J Mol Catal A: Chem. 2006;260(1-2):288–294. doi: 10.1016/j.molcata.2006.07.034. [DOI] [Google Scholar]
  • 28.Wei X., Liu J., Zhang G. L., Jiang Z. L., Zhou C. H., Luo K., Xie R. G. An effective methodology to novel larger imidazolium cyclophanes. Lett Org Chem. 2005;2:507–511. doi: 10.2174/1570178054640804. [DOI] [Google Scholar]
  • 29.Gao G., Xiao R., Yuan Y., Zhou C. H., Xie R. G. Efficient imidazolium catalysts forbenzoin condensation. J Chem Res. 2002;6:262–263. doi: 10.3184/030823402103172130. [DOI] [Google Scholar]
  • 30.Wu J., Mi J. L., Zhou C. H. Advance in histamine H3 receptor ligands. Chin Pharm J (in Chinese) 2007;46(6):404–409. [Google Scholar]
  • 31.Song C. Z., Zhou C. H., Yuan Y. Advance in sulfonamides as carbonic anhydrase inhibitors. Chin J New Drugs (in Chinese) 2007;16(18):1438–1444. [Google Scholar]
  • 32.Meng J. P., Lu Y. H., Yibulayin H., Zhou C. H. Advances in the research of benzimidazole compounds as enzyme inhibitors. Chin J Biochem Pharm (in Chinese) 2008;29(6):422–425. [Google Scholar]
  • 33.Yu K. G., Zhou C. H., Li D. H. Advances in the macrocyclic drugs. Chin Pharm J (in Chinese) 2008;43(7):481–488. [Google Scholar]
  • 34.Clarke M. J., Zhu F. C., Frasca D. R. Non-platinum chemotherapeutic metallopharmaceuticals. Chem Rev. 1999;99(9):2511–2533. doi: 10.1021/cr9804238. [DOI] [PubMed] [Google Scholar]
  • 35.Ott I., Gust R. Non platinum metal complexes as anti-cancer drugs. Arch Pharm Chem Life Sci. 2007;340(3):117–126. doi: 10.1002/ardp.200600151. [DOI] [PubMed] [Google Scholar]
  • 36.Dai G. F., Wang M. W. Progress in pharmaceutical applications of cyclodextrin and its derivatives. Chin J New Drugs (in Chinese) 2005;14(11):1261–1264. [Google Scholar]
  • 37.Deng S. M. Dissertation for the Doctoral Degree. Guangzhou: South China University of Technology; 1998. Study on the drug-Cyclodextrin supramolecular system. [Google Scholar]
  • 38.Beni S., Szakacs Z., Cserniak O., Barcza L., Noszal B. Cyclodextrin/imatinib complexation: Binding mode and charge dependent stabilities. Eur J Pharm Sci. 2007;30(2):167–174. doi: 10.1016/j.ejps.2006.10.008. [DOI] [PubMed] [Google Scholar]
  • 39.Horvath G., Premkumar T., Boztas A., Lee E., Jon S., Geckeler K. E. Supramolecular nanoencapsulation as a tool: Solubilization of the anticancer drug trans-dichloro(dipyridine)platinum(II) by complexation with β-cyclodextrin. Mol Pharm. 2008;5(2):358–363. doi: 10.1021/mp700144t. [DOI] [PubMed] [Google Scholar]
  • 40.Melo P. S., Justo G. Z., Azevedo M. B. M., Duran N., Haun M. Violacein and its β-cyclodextrin complexes induce apoptosis and differentiation in HL60 cells. Toxicology. 2003;186(3):217–225. doi: 10.1016/S0300-483X(02)00751-5. [DOI] [PubMed] [Google Scholar]
  • 41.Wang F. J., Blanco E., Ai H., Boothman D. A., Gao J. M. Modulating β-lapachone release from polymer millirods through cyclodextrin complexation. J Pharm Sci. 2006;95(10):2309–2319. doi: 10.1002/jps.20721. [DOI] [PubMed] [Google Scholar]
  • 42.Menuel S., Joly J. P., Courcot B., Elysee J., Ghermani N. E., Marsura A. Synthesis and inclusion ability of a bis-β-cyclodextrin pseudocryptand towards busulfan anticancer agent. Tetrahedron. 2007;63(7):1706–1714. doi: 10.1016/j.tet.2006.10.070. [DOI] [Google Scholar]
  • 43.Liu Y., Chen G. S., Chen Y., Cao D. X., Ge Z. Q., Yuan Y. J. Inclusion comp lexes of paclitaxel and oligo (ethylenediamino) bridged bis(β-cyclodextrin)s: Solubilization and antitumor activity. Bioorg Med Chem. 2004;12(22):5767–5775. doi: 10.1016/j.bmc.2004.08.040. [DOI] [PubMed] [Google Scholar]
  • 44.Jong M. R., Knegtel R. M. A., Grootenhuis P. D. J., Huskens J., Reinhoudt D. N. A method to identify and screen libraries of guests that complex to a synthetic host. Angew Chem Int Ed. 2002;41(6):1004–1008. doi: 10.1002/1521-3773(20020315)41:6<1004::AID-ANIE1004>3.0.CO;2-8. [DOI] [PubMed] [Google Scholar]
  • 45.Krause-Heuer A. M., Wheate N. J., Tilby M. J., Pearson D. G., Ottley C. J., Aldrich-Wright J. R. Substituted β-cyclodextrin and calix[4]arene as encapsulatory vehicles for platinum(II)-based DNA intercalators. Inorg Chem. 2008;47(15):6880–6888. doi: 10.1021/ic800467c. [DOI] [PubMed] [Google Scholar]
  • 46.Comuzzi C., Cogoi S., Overhand M., Marel G. A. V., Overkleeft H. S., Xodo L. E. Synthesis and biological evaluation of new pentaphyrin macrocycles for photodynamic therapy. J Med Chem. 2006;49(1):196–204. doi: 10.1021/jm050831l. [DOI] [PubMed] [Google Scholar]
  • 47.Desroches M. C., Bautista-Sanchez A., Lamotte C., Labeque B., Auchère D., Farinotti R., Maillard P., Grierson D. S., Prognon P., Kasselouri A. Pharmacokinetics of a tri-glucoconjugated 5,10,15-(meta)-trihydroxyphenyl-20-phenyl porphyrin photosensitizer for PDT. A single dose study in the rat. J Photochem Photobiol B: Biol. 2006;85(1):56–64. doi: 10.1016/j.jphotobiol.2006.03.008. [DOI] [PubMed] [Google Scholar]
  • 48.Yu K. G., Zhou C. H., Li D. H. Recent progress of porphyrin-based anticancer drugs. Chem Res Appl (in Chinese) 2007;19(12):1296–1303. [Google Scholar]
  • 49.Nyman E. S., Hynninen P. H. Research advances in the use of tetrapyrrolic photosensitizers for photodynamic therapy. J Photochem Photobiol B: Biol. 2004;73(1–2):1–28. doi: 10.1016/j.jphotobiol.2003.10.002. [DOI] [PubMed] [Google Scholar]
  • 50.Ma J. S. Development of second generational porphyrin-based photosensitizers. Photogra Sci Photochem (in Chinese) 2002;20(2):131–148. [Google Scholar]
  • 51.Hirakaa K., Kanehisaa M., Tamaia M., Asayamaa S., Nagaokaa S., Oyaizuc K., Yuasab M., Kawakami H. Preparation of pH-sensitive liposomes retaining SOD mimic and their anticancer effect. Colloids Surf B: Biointerfaces. 2008;67(1):54–58. doi: 10.1016/j.colsurfb.2008.07.014. [DOI] [PubMed] [Google Scholar]
  • 52.Asayama S., Kasugai N., Kubota S., Nagaoka S., Kawakami H. Superoxide dismutase as a target enzyme for Fe-porphyrin-induced cell death. J Inorg Biochem. 2007;101(2):261–266. doi: 10.1016/j.jinorgbio.2006.09.029. [DOI] [PubMed] [Google Scholar]
  • 53.Wang Y., He Q. Y., Che C. M., Tsao S. W., Sun R. W. Y., Chiu J. F. Modulation of gold(II) porphyrin 1a-induced apoptosis by mitogen-activated protein kinase signaling pathways. Biochem Pharm. 2008;75(6):1282–1291. doi: 10.1016/j.bcp.2007.11.024. [DOI] [PubMed] [Google Scholar]
  • 54.Wang Y., He Q. Y., Raymond Sun W. Y., Che C. M., Chiu J. F. Cellular pharmacological properties of gold(III) porphyrin 1a, a potential anticancer drug lead. Eur J Pharmacol. 2007;554(2-3):113–122. doi: 10.1016/j.ejphar.2006.10.034. [DOI] [PubMed] [Google Scholar]
  • 55.Li D.H., Diao J. L., Yu K. G., Zhou C. H. Synthesis and anticancer activities of porphyrin induced anticancer drugs. Chin Chem Lett. 2007;18(11):1331–1334. [Google Scholar]
  • 56.Zhuang Y. Y., Zhou C. H., Wang Y. F., Li D. H. Advances of nitrogen mustard compounds in antitumor agents. Chin Pharm J (in Chinese) 2008;44(17):1281–1287. [Google Scholar]
  • 57.Cai J L, Li S, Zhou C H, Gan L L. Advances in imidazoles as anti-tumor agents. Chin J New Drugs (in Chinese), 2009, 18(7): in press
  • 58.Yu K. G., Liu J. C., Zhou C. H., Diao J. L., Xu T., Li D. H. Study on synthesis of porphyrin-nitroimidazole derivatives and their radiosensitization. Chin J Med Chem (in Chinese) 2008;18(6):414–419. [Google Scholar]
  • 59.Meng J P, Geng R X, Zhou C H, Gan L L. Advances in the research of benzimidazole compounds. Chin J New Drugs (in Chinese), 2009, 18(8): in press
  • 60.Mi J. L., Wu J., Zhou C. H. Advances in the triazoles as anticancer drugs. West China J Pharm Sci (in Chinese) 2008;23(1):84–86. [Google Scholar]
  • 61.Bai X., Zhou C. H., Mi J. L. Research and application of triazoles. Chem Res Appl (in Chinese) 2007;19(7):721–729. [Google Scholar]
  • 62.Zhou C. H., Hassner A. Synthesis and anticancer activity of novel chiral glucose derived bis-imidazoles and their analogs. Carbohydrates Res. 2001;333(4):313–326. doi: 10.1016/S0008-6215(01)00154-9. [DOI] [PubMed] [Google Scholar]
  • 63.Huang J., Zhou C. H. Progress in nitroimidazoles as medicinal agents. Chin Clin J Traditional Chin West Med (in Chinese) 2007;7(7):538–542. [Google Scholar]
  • 64.Jamieson E. R., Lippard S. J. Structure, recognition, and processing of cisplatin-DNA adducts. Chem Rev. 1999;99(9):2467–2498. doi: 10.1021/cr980421n. [DOI] [PubMed] [Google Scholar]
  • 65.Qu P., He H., Liu X. H. Antitumor activity and mechanism of rhodium complexes. Prog Chem (in Chinese) 2006;18(12):1646–1651. [Google Scholar]
  • 66.Liu W. P., Zhang Y. L., Sun R. L. Future development of platinum anticancer drugs. Precious Met (in Chinese) 2005;26(1):47–52. [Google Scholar]
  • 67.Bagrova S. G. Results of phaseIIclinical trials of cycloplatam in refractory solid tumors. Vopr Onkol. 2001;47(6):752–756. [PubMed] [Google Scholar]
  • 68.Raynaud F. I., Boxall F. E., Goddard P. M., Valenti M., Jones M., Murrer B. A., Abrams M., Kelland L. R. cis-Amminedichloro(2-methylpyridine) platinum(II) (AMD473), a novel sterically hindered platinum complex: In vivo activity, toxicology, and pharmacokinetics in mice. Clin Cancer Res. 1997;3(11):2063–2074. [PubMed] [Google Scholar]
  • 69.Brabec V., Kašpárková J., Vrána O., Nováková O., Cox J. W., Qu Y., Farrell N. DNA modification by a novel bifunctional trinuclear platinum antitumor agent. Biochem. 1999;38(21):6781–6790. doi: 10.1021/bi990124s. [DOI] [PubMed] [Google Scholar]
  • 70.Ulrich S, Milod S. DE Patent, 19 824 653, 1999-08-26
  • 71.Bjelosevic H., Spégel C., Snygg Å. S., Gorton L., Elmrothc S. K. C., Perssona T. Synthesis and structural characterisation of novel platinum-based drug candidates with extended functionality by incorporation of bis(diphenylphosphino)ferrocene units as metal chelators. Tetrahedron. 2006;62(18):4519–4527. doi: 10.1016/j.tet.2006.02.057. [DOI] [Google Scholar]
  • 72.Gupta A., Mandal S. K., Leblanc V., Descoeaux C., Asselin, Bérubé G. Synthesis and cytotoxic activity of benzopyran-based platinum(II) complexes. Bioorg Med Chem Lett. 2008;18(14):3982–3987. doi: 10.1016/j.bmcl.2008.06.013. [DOI] [PubMed] [Google Scholar]
  • 73.Descôteaux C., Provencher-Mandeville J., Mathieu I., Perron V., Mandal S. K., Asselin, Bérubé G. Synthesis of 17β-estradiol platinum(II) complexes: biological evaluation on breast cancer cell lines. Bioorg Med Chem Lett. 2003;13(22):3927–3931. doi: 10.1016/j.bmcl.2003.09.011. [DOI] [PubMed] [Google Scholar]
  • 74.Gagnon V., St-Germain M. È., Descôteaux C., Provencher-Mandeville J., Parent S., Mandal S. K., Asselin E., Bérubé G. Biological evaluation of novel estrogen-platinum(II) hybrid molecules on uterine and ovarian cancers-Molecular modeling studies. Bioorg Med Chem Lett. 2004;14(23):5919–5924. doi: 10.1016/j.bmcl.2004.09.015. [DOI] [PubMed] [Google Scholar]
  • 75.Perron V., Rabouin D., Asselin, Parent S., Gaudreault R. C., Bérubé G. Synthesis of 17β-estradiol-linked platinum(II) complexes and their cytocidal activity on estrogen-dependent and-independent breast tumor cells. Bioorg Chem. 2005;33(1):1–15. doi: 10.1016/j.bioorg.2004.06.009. [DOI] [PubMed] [Google Scholar]
  • 76.Berube G. US Patent, 7 153 844, 2004-01-08
  • 77.N’soukpoé-Kossi C. N., Descoeaux C., Asselin E., Tajmir-Riahi H. A., Bérubé G. DNA Interaction with novel antitumor estradiol-platinum (II) hybrid molecule: A comparative study with cisplatin drug. DNA Cell Biol. 2008;27(2):101–107. doi: 10.1089/dna.2007.0669. [DOI] [PubMed] [Google Scholar]
  • 78.Hall M. D., Mellor H. R., Callaghan R., Hambley T. W. Basis for design and development of platinum(IV) anticancer complexes. J Med Chem. 2007;50(15):3403–3411. doi: 10.1021/jm070280u. [DOI] [PubMed] [Google Scholar]
  • 79.Kašpárková J., Nováková O., Vrána O., Intini F., Natile G., Brabec V. Molecular aspects of antitumor effects of a new platinum(IV) drug. Mol Pharmacol. 2006;70(50):1708–1719. doi: 10.1124/mol.106.027730. [DOI] [PubMed] [Google Scholar]
  • 80.Bednarski P. J., Grünert R., Zielzki M., Wellner A., Mackay F. S., Sadler P. J. Light-activated destruction of cancer cell nuclei by platinum diazide complexes. Chem Biol. 2006;13(1):61–67. doi: 10.1016/j.chembiol.2005.10.011. [DOI] [PubMed] [Google Scholar]
  • 81.Mackay F. S., Woods J. A., Moseley H., Ferguson J., Dawson A., Parsons S., Sadler P. J. A photoactivated trans-diammine platinum complex as cytotoxic as cisplatin. Chemistry. 2006;12(11):3155–3161. doi: 10.1002/chem.200501601. [DOI] [PubMed] [Google Scholar]
  • 82.Chen Q., Huang Z., Chen H., Shapiro H., Beckers J., Hetzel F. W. Improvement of tumor response by manipulation of tumor oxygenation during photodynamic therapy. Photochem Photobiol. 2002;76(2):197–203. doi: 10.1562/0031-8655(2002)076<0197:IOTRBM>2.0.CO;2. [DOI] [PubMed] [Google Scholar]
  • 83.Kwon Y. E., Whang K. J., Park Y. J., Kim K. H. Synthesis, characterization and antitumor activity of novel octahedral Pt(IV) complexes. Bioorg Med Chem. 2003;11(8):1669–1676. doi: 10.1016/S0968-0896(03)00044-0. [DOI] [PubMed] [Google Scholar]
  • 84.Zhang C. X., Lippard S. J. New metal complexes as potential therapeutics. Curr Opin Chem Biol. 2003;7(4):481–489. doi: 10.1016/S1367-5931(03)00081-4. [DOI] [PubMed] [Google Scholar]
  • 85.Enzo A., Angela B., Elisabetta I. International conference on DNA conformation, modification and recognition in biomedcine. Brno Czech Republic. 2000;1:72–73. [Google Scholar]
  • 86.Chai X. H., Wang F. L., Huang J., Zhang J. Progress in investigation of metallodrugs. Chem Agen (in Chinese) 2008;30(2):99–104. [Google Scholar]
  • 87.Clarke M. J. Ruthenium metallopharmaceuticals. Coord Chem Rev. 2003;236(1–2):209–233. doi: 10.1016/S0010-8545(02)00312-0. [DOI] [Google Scholar]
  • 88.Vargiu A. V., Robertazzi A., Magistrato A., Ruggerone P., Carloni P. The hydrolysis mechanism of the anticancer ruthenium drugs NAMI-A and ICR investigated by DFT-PCM calculations. J Phys Chem B. 2008;112(14):4401–4409. doi: 10.1021/jp710078y. [DOI] [PubMed] [Google Scholar]
  • 89.Sanna B., Debidda M., Pintus G., Tadolini B., Posadino A. M., Bennardini F., Sava G., Ventura C. The anti-metastatic agent imidazolium transimidazoledimethylsulfoxidetetrachlororuthenate induces endothelial cell apoptosis by inhibiting the mitogen-activiated protein kinase/extracellular signal-regulated kinase signaling pathway. Arch Biochem Biophys. 2002;403(2):209–218. doi: 10.1016/S0003-9861(02)00218-7. [DOI] [PubMed] [Google Scholar]
  • 90.Gopal Y. N. V., Konuru N., Kondapi A. K. Topoisomerase II antagonism and anticancer activity of coordinated derivatives of [RuCl2(C6H6)-(dmso)] Arch Biochem Biophys. 2002;401(1):53–62. doi: 10.1016/S0003-9861(02)00037-1. [DOI] [PubMed] [Google Scholar]
  • 91.Cebrián-Losantos B., Reisner E., Kowol C. R., Roller A., Shova S., Arion V. B., Keppler B. K. Synthesis and reactivity of the aquation product of the antitumor complex trans-[RuIIICl4(indazole)2]−. Inorg Chem. 2008;47(14):6513–6523. doi: 10.1021/ic800506g. [DOI] [PubMed] [Google Scholar]
  • 92.Korfel A., Scheulen M. E., Schmoll H. J., Gründel O., Harstrick A., Knoche M., Fels L. M., Skorzec M., Bach F., Baumgart J., Safi G., Seeber S., Thiel E., Berdel W. E. Phase I clinical and pharmacokinetic study of titanocene dichloride in adults with advanced solid tumors. Clin Cancer Res. 1998;4(11):2701–2708. [PubMed] [Google Scholar]
  • 93.Lum B. L., Srivanas S., Beck J. T., Vesole D., Largey M., Valone F. H., Sayre P. H. Phase I trial of oral gallium maltolate in refractory malignancies. Proc. Am Soc Clin Oncol. 2003;22:943. [Google Scholar]
  • 94.Foteeva L. S., Stolyarova N. V., Timerbaev A. R., Keppler B. K. Capillary electrophoretic assay for the stability of tris(8-quinolinolato) gallium(III) in tablet formulations. J Pharm Biomed Anal. 2008;48(1):218–222. doi: 10.1016/j.jpba.2008.05.017. [DOI] [PubMed] [Google Scholar]
  • 95.Heffeter P., Jungwirth U., Jakupec M., Hartinger C., Galanski M., Elbling L., Micksche M., Keppler B., Berger W. Resistance against novel anticancer metal compounds: Difference and similarities. Drug Resistance Updates. 2008;11(1-2):1–16. doi: 10.1016/j.drup.2008.02.002. [DOI] [PubMed] [Google Scholar]
  • 96.Rieter W. J., Pott K. M., Taylor K. M. L., Lin W. Nanoscale coordination polymers for platinum-based anticancer drug delivery. J Am Chem Soc. 2008;130(35):11584–11585. doi: 10.1021/ja803383k. [DOI] [PubMed] [Google Scholar]
  • 97.Moses M. A., Brem H., Langer R. Advancing the field of drug delivery: taking aim at cancer. Cancer Cell. 2003;4(5):337–341. doi: 10.1016/S1535-6108(03)00276-9. [DOI] [PubMed] [Google Scholar]
  • 98.Vail D. M., Amantea M. A., Colbern G. T., Martin F. J., Hilger R. A., Working P. K. Pegylated liposomal doxorubicin: proof of principle using preclinical animal models and pharmacokinetic studies. Semin Oncol. 2004;31(13):16–35. doi: 10.1053/j.seminoncol.2004.08.002. [DOI] [PubMed] [Google Scholar]
  • 99.Panyam J., Labhasetwar V. Biodegradable nanoparticles for drug and gene delivery to cells and tissue. Adv Drug Delivery Rev. 2003;55(3):329–347. doi: 10.1016/S0169-409X(02)00228-4. [DOI] [PubMed] [Google Scholar]
  • 100.Ferrari M. Cancer nanotechnology: opportunities and challenges. Nat Rev Cancer. 2005;5(3):161–171. doi: 10.1038/nrc1566. [DOI] [PubMed] [Google Scholar]
  • 101.Fonseca C., Simões S., Gaspar R. Paclitaxel-loaded PLGA nanoparticles: Preparation, phsiochemical characterization and in vitro antitumoral activity. J Controlled Release. 2002;83(2):273–286. doi: 10.1016/S0168-3659(02)00212-2. [DOI] [PubMed] [Google Scholar]
  • 102.Brannon-Peppas L., Blanchette J. O. Nanoparticle and targeted systems for cancer therapy. Adv Drug Delivery Rev. 2004;56(11):1649–1659. doi: 10.1016/j.addr.2004.02.014. [DOI] [PubMed] [Google Scholar]
  • 103.Yoo H. S., Park T. G. In vitro and in vivo anti-tumor activities of nanoparticles based on doxorubicin-PLGA conjugates. J Controlled Release. 2000;68(3):419–431. doi: 10.1016/S0168-3659(00)00280-7. [DOI] [PubMed] [Google Scholar]
  • 104.Mitra S., Gaur U., Ghosh P. C., Maitra A. N. Tumour targeted delivery of encapsulated dextran-doxorubicin conjugate using chitosan nanoparticles as carrier. J Controlled Release. 2001;74(1-3):317–323. doi: 10.1016/S0168-3659(01)00342-X. [DOI] [PubMed] [Google Scholar]
  • 105.Savic R., Luo L., Eisenberg A., Maysinger D. Micell nanocontainers distribute to defined cytoplasmic organelles. Science. 2003;300(5619):615–618. doi: 10.1126/science.1078192. [DOI] [PubMed] [Google Scholar]
  • 106.Hu Y. Q., Kim M. S., Kim B. S., Lee D. S. Synthesis and pH-dependent micellization of 2-(dIIsopropylamino)ethyl methacrylate based amphiphilic diblock copolymers via RAFT polymerization. Polymer. 2007;48(12):3437–3443. doi: 10.1016/j.polymer.2007.04.011. [DOI] [Google Scholar]
  • 107.Sutton D., Nasongkla N., Blanco E., Gao J. Functionalized micellar systems for cancer targeted drug delivery. Pharm Res. 2007;24(6):1029–1046. doi: 10.1007/s11095-006-9223-y. [DOI] [PubMed] [Google Scholar]
  • 108.Yang X. Q., Chen Y. H., Yuan R. X., Chen G. H., Blanco E., Gao J. M., Shuai X. T. Folate-encoded and Fe3O4-loaded polymeric micelles for dual targeting of cancer cells. Polymer. 2008;49(16):3477–3485. doi: 10.1016/j.polymer.2008.06.005. [DOI] [Google Scholar]
  • 109.Xu P. S., Kirk E. A. V., Murdoch W. J., Zhan Y. H., Isaak D. D., Radosz M., Shen Y. Q. Anticancer efficacies of cisplatin releasing pH-responsive nanoparticles. Biomacromolecules. 2006;7(3):829–835. doi: 10.1021/bm050902y. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 110.Feazell R. P., Nakayama-Ratchford N., Dai H. J., Lippard S. J. Soluble single-walled carbon nanotubes as longboat delivery systems for platinum(IV) anticancer drug design. J Am Chem Soc. 2007;129(27):8438–8439. doi: 10.1021/ja073231f. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 111.Shi G. Y. Progress in the study of non-steroidal anti-imflammatory drugs. Chin J New Drugs (in Chinese) 1999;8(9):699–601. [Google Scholar]
  • 112.Weder J. E., Dillon C. T., Hambley T. W., Kennedy B. J., Lay P. A., Biffin J. R., Regtop H. L., Davies N. M. Copper complexes of non-steroidal anti-inflammatory drugs: an opportunity yet to be realized. Coord Chem Rev. 2002;232(1–2):95–126. doi: 10.1016/S0010-8545(02)00086-3. [DOI] [Google Scholar]
  • 113.Moya-Hernández M. R., Mederos A., Domínguez S., Orlandinid A., Ghilardi C. A., Cecconi F., González-Vergara E., Rojas-Hernández A. Speciation study of the anti-inflammatory drug tenoxicam (Htenox) with Cu(II): X-ray crystal structure of [Cu(tenox)2(py)2]·EtOH. J Inorg Biochem. 2003;95(2–3):131–140. doi: 10.1016/S0162-0134(03)00095-3. [DOI] [PubMed] [Google Scholar]
  • 114.Morgan Y. R., Turner P., Kennedy B. J., Hambley T. W., Lay P. A., Biffin J. R., Regtop H. L., Warwick B. Preparation and characterization of dinuclear copper-indomethacin anti-inflammatory drugs. Inorg Chim Acta. 2001;324(1-2):150–161. doi: 10.1016/S0020-1693(01)00570-9. [DOI] [Google Scholar]
  • 115.Trinchero A., Bonora S., Tinti A., Fini G. Spectroscopic behavior of copper complexes of nonsteroidal anti-inflammatory drugs. Biopolymers. 2004;74(1-2):120–124. doi: 10.1002/bip.20057. [DOI] [PubMed] [Google Scholar]
  • 116.Weder J. E., Hambley T. W., Kennedy B. J., Lay P. A., MacLachlan D., Bramley R., Delfs C. D., Murray K. S., Moubaraki B., Warwick B., Biffin J. R., Regtop H. L. Anti-inflammatory dinuclear copper(II) complexes with indomethacin. Synthesis, magnetism and EPR spectroscopy. crystal structure of the N,N-dimethylformamide adduct. Inorg Chem. 1999;38(8):1736–1744. doi: 10.1021/ic981100x. [DOI] [PubMed] [Google Scholar]
  • 117.Chaviara A. T., Christidis P. C., Papageorgiou A., Chrysogelou E., Hadjipavlou-Litina D. J., Bolos C. A. In vivo anticancer, anti-inflammatory, and toxicity studies of mixed-ligand Cu(II) complexes of dien and its Schiff dibases with heterocyclic aldehydes and 2-amino-2-thiazoline. crystal structure of [Cu(dien)(Br)(2a-2tzn)] (Br)(H2O). J Inorg Biochem. 2005;99(11):2102–2109. doi: 10.1016/j.jinorgbio.2005.07.011. [DOI] [PubMed] [Google Scholar]
  • 118.Zvimba J. N., Jackson G. E. Copper chelating anti-inflammatory agents; N1-(2-aminoethyl)-N2-(pyridin-2-ylmethyl)-ethane-1,2-diamine and N-(2-(2-aminoethylamino)ethyl)picolinamide: An in vitro and in vivo study. J Inorg Biochem. 2007;101(1):148–158. doi: 10.1016/j.jinorgbio.2006.09.006. [DOI] [PubMed] [Google Scholar]
  • 119.Zhou Q. D., Hambley T. W., Kennedy B. J., Lay P. A., Turner P., Warwick B., Biffin J. R., Regtop H. L. Syntheses and characterization of antiinflammatory dinuclear and mononuclear zinc indomethacin complexes. crystal structures of [Zn2(Indomethacin)4(L)2] (L = N,N-dimethyl-acetamide, pyridine, 1-methyl-2-pyrrolidinone) and [Zn(Indomethacin)2(L1)2] (L1 = ethanol, methanol) Inorg Chem. 2000;39(17):3742–3748. doi: 10.1021/ic991477i. [DOI] [PubMed] [Google Scholar]
  • 120.Zhou Q. D., Hambley T. W., Kennedy B. J., Lay P. A. XAFS studies of anti-inflammatory dinuclear and mononuclear Zn(II) complexes of indomethacin. Inorg Chem. 2003;42(25):8557–8566. doi: 10.1021/ic034049s. [DOI] [PubMed] [Google Scholar]
  • 121.Jain S., Jain N. K., Pitre K. S. Electrochemical analysis and analgesic behavior of Zn(II)-baclofen complex. J Pharm Biomed Anal. 2003;31(5):1035–1039. doi: 10.1016/S0731-7085(02)00700-8. [DOI] [PubMed] [Google Scholar]
  • 122.Shaheen F., Badshah A., Gielen M., Gieck C., Jamil M., Vos D. D. Synthesis, characterization, in vitro cytotoxicity and anti-inflammatory activity of palladium(II) complexes with tertiary phosphines and heterocyclic thiolates: Crystal structure of [PdC28H19N8PS2] J Inorg Biochem. 2008;693(6):1117–1126. [Google Scholar]
  • 123.Kovala-Demertzi D. Recent advances on non-steroidal anti-inflammatory drugs, NSAIDs: Organotin complexes of NSAIDs. J Organomet Chem. 2006;691(8):1767–1774. doi: 10.1016/j.jorganchem.2005.11.058. [DOI] [Google Scholar]
  • 124.Ribeiro G., Benadiba M., Colquhoun A., Silva D. D. O. Diruthenium(II,III) complexes of ibuprofen, aspirin, naproxen and indomethacin non-steroidal anti-inflammatory drugs: Synthesis, characterization and their effects on tumor-cell proliferation. Polyhedron. 2008;27(3):1131–1137. doi: 10.1016/j.poly.2007.12.011. [DOI] [Google Scholar]
  • 125.Ashfaq M., Khan M. I., Baloch M. K., Malik A. Biologically potent organotin(IV) complexes of 2-maleimidoacetic acid. J Organomet Chem. 2004;689(1):238–245. doi: 10.1016/j.jorganchem.2003.10.007. [DOI] [Google Scholar]
  • 126.Ashfaq M. Synthesis of novel bioactive phthalimido-4-methyl pentanoateorganotin(IV) esters with spectroscopic investigation. J Organomet Chem. 2006;691(8):1803–1808. doi: 10.1016/j.jorganchem.2005.12.031. [DOI] [Google Scholar]
  • 127.Partyka M., Au B., Evans C. Cyclodextrins as phototoxicity inhibitors in drug formulations: studies on model systems involving naproxen and beta-cyclodextrin. J Photoch Photobio A. 2001;140(1):67–74. doi: 10.1016/S1010-6030(01)00386-0. [DOI] [Google Scholar]
  • 128.Yano H., Hirayama F., Kamada M., Arima H., Uekama K. Colon-specific delivery of prednisolone-appended α-cyclodextrin conjugate: Alleviation of systemic side effect after oral administration. J Controlled Release. 2002;79(1-3):103–112. doi: 10.1016/S0168-3659(01)00532-6. [DOI] [PubMed] [Google Scholar]
  • 129.Zhang Y., Wang J. Z., Wu Y. J. Progress of pharmaceutical studies on superoxide dismutase. Acta Pharm Sinica (in Chinese) 2003;38(1):71–74. [Google Scholar]
  • 130.Valdivia A., Pérez Y., Cao R., Baños M., García A., Villalonga R. Bienzymatic supramolecular complex of catalase modified with cyclodextrin-branched carboxymethylcellulose and superoxide dismutase: Stability and anti-inflammatory properties. Macromol Biosci. 2007;7(1):70–75. doi: 10.1002/mabi.200600166. [DOI] [PubMed] [Google Scholar]
  • 131.Wen X. H., Liu Z. Y., Zhu T. Q., Zhu M. Q., Jiang K. Z., Huang Q. Q. Evidence for the 2:1 molecular recognition and inclusion behaviour between β-and γ-cyclodextrins and cinchonine. Bioorg Chem. 2004;32(4):223–233. doi: 10.1016/j.bioorg.2004.04.004. [DOI] [PubMed] [Google Scholar]
  • 132.Wong J. W., Yuen K. H. Improved oral bioavailability of artemisinin through inclusion complexation with β-and γ-cyclodextrins. Int J Pharm. 2001;227(1-2):177–185. doi: 10.1016/S0378-5173(01)00796-7. [DOI] [PubMed] [Google Scholar]
  • 133.Dive D., Biot C. Ferrocene conjugates of chloroquine and other antimalarials: The development of ferroquine, a new antimalarial. Chem Med Chem. 2008;3(3):383–391. doi: 10.1002/cmdc.200700127. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 134.Chibale K., Moss J. R., Blackie M., Schalkwyk D. V., Smith P. J. New amine and urea analogs of ferrochloroquine: synthesis, antimalarial activity in vitro and electrochemical studies. Tetrahedron Lett. 2000;41(32):6231–6235. doi: 10.1016/S0040-4039(00)01036-4. [DOI] [Google Scholar]
  • 135.Biot C., Dessolin J., Ricard I., Dive D. Easily synthesized antimalarial ferrocene triazacyclononane quinoline conjugates. J Organomet Chem. 2004;689(25):4678–4682. doi: 10.1016/j.jorganchem.2004.04.036. [DOI] [Google Scholar]
  • 136.Biot C., Delhaes L., Maciejewski L. A., Mortuaire M., Camus D., Dive D., Brocard J. S. Synthetic ferrocenic mefloquine and quinine analogues as potential antimalarial agents. Eur J Med Chem. 2000;35(7-8):707–714. doi: 10.1016/S0223-5234(00)00178-1. [DOI] [PubMed] [Google Scholar]
  • 137.Biot C., Pradines B., Sergeant M. H., Gut J., Rosenthal P. J., Chibale K. Design, synthesis, and antimalarial activity of structural chimeras of thiosemicarbazone and ferroquine analogues. Bioorg Med Chem Lett. 2007;17(23):6434–6438. doi: 10.1016/j.bmcl.2007.10.003. [DOI] [PubMed] [Google Scholar]
  • 138.Guillo J., Moreau S., Mouray E., Sinou V., Forfar I., Fabre S. B., Desplat V., Millet P., Parzy D., Jarry C., Grellier P. New ferrocenic pyrrolo[1,2-a] quinoxaline derivatives: Synthesis, and in vitro antimalarial activity. Bioorg Med Chem. 2008;16(20):9133–9144. doi: 10.1016/j.bmc.2008.09.038. [DOI] [PubMed] [Google Scholar]
  • 139.Gokhale N. H., Padhye S. B., Billington D. C., Rathbone D. L., Croft S. L., Kendrick H. D., Anson C. E., Powell A. K. Synthesis and characterization of copper(II) complexes of pyridine-2-carboxami-drazones as potent antimalarial agents. Inorg Chim Acta. 2003;349:23–29. doi: 10.1016/S0020-1693(03)00047-1. [DOI] [Google Scholar]
  • 140.Gokhale N. H., Padhye S. B., Croft S. L., Kendrick H. D., Davies W., Anson C. E., Powell A. K. Transition metal complexes of buparvaquone as potent new antimalarial agents 1. Synthesis, X-ray crystal-structures, electrochemistry and antimalarial activity against plasmodium falciparum. J Inorg Biochem. 2003;95(4):249–258. doi: 10.1016/S0162-0134(03)00134-X. [DOI] [PubMed] [Google Scholar]
  • 141.Gokhale N. H., Shirisha K., Padhye S. B., Croft S. L., Kendrick H. D., Mckee V. Metalloantimalarials: Synthesis, X-ray crystal structure of potent antimalarial copper(II) complex of arylazo-4-hydroxy-1, 2-naphthoquinone. Bioorg Med Chem Lett. 2006;16(2):430–432. doi: 10.1016/j.bmcl.2005.09.061. [DOI] [PubMed] [Google Scholar]
  • 142.Dadachova E. Preparation of 198Au(I)-labelled gold-chloroquine complex [198Au(PPh3)(CQ)]PF6 as a petential antimalarial agent. J Labelled Cpd Radiopharm. 1999;42(3):287–292. doi: 10.1002/(SICI)1099-1344(199903)42:3<287::AID-JLCR189>3.0.CO;2-O. [DOI] [Google Scholar]
  • 143.Navarro M., Pekerar S., Pérez H. A. Synthesis, characterization and antimalarial activity of new iridium-chloroquine complexes. Polyhedron. 2007;26(12):2420–2424. doi: 10.1016/j.poly.2006.12.010. [DOI] [Google Scholar]
  • 144.Yuan Y., Zhou C. H., Liu Q., Song C. Z. New synthetic antibacterial agents. Chin J New Drugs (in Chinese) 2007;16(5):343–350. [Google Scholar]
  • 145.Zhang Y. Progress in research of quinolone antibacteials. Chin J New Drugs. 2006;15(16):1344–1356. [Google Scholar]
  • 146.Mitscher L. A. Bacterial topoisomerase inhibitors: Quinolone and pyridone antibacterial. Chem Rev. 2005;105(2):559–592. doi: 10.1021/cr030101q. [DOI] [PubMed] [Google Scholar]
  • 147.Psomas G., Tarushi A., Efthimiadou E. K., Sanakis Y., Raptopoulou C. P., Katsaros N. Synthesis, structure and biological activity of copper(II) complexes with oxolinic acid. J Inorg Biochem. 2006;100(11):1764–1773. doi: 10.1016/j.jinorgbio.2006.06.012. [DOI] [PubMed] [Google Scholar]
  • 148.Tarushi A., Efthimiadou E. K., Christofis P., Psomas G. Neutral mononuclear dioxomolybdenum(VI) and dioxouranium(VI) complexes of oxolinic acid: Characterization and biological evaluation. Inorg Chim Acta. 2007;360(14):3978–3986. doi: 10.1016/j.ica.2007.05.041. [DOI] [Google Scholar]
  • 149.Efthimiadou E. K., Sanakis Y., Katsaros N., Karaliota A., Psomas G. Transition metal complexes with the quinolone antibacterial agent pipemidic acid: Synthesis, characterization and biological activity. Polyhedron. 2007;26(5):1148–1158. doi: 10.1016/j.poly.2006.10.017. [DOI] [Google Scholar]
  • 150.Li Y. X., Chen Z. F., Xiong R. G., Xue Z., Ju H. X., You X. Z. A mononuclear complex of norfloxacin with silver(I) and its properties. Inorg Chem Commun. 2003;6(7):819–822. doi: 10.1016/S1387-7003(03)00115-1. [DOI] [Google Scholar]
  • 151.Refat M. S. Synthesis and characterization of norfloxacin-transition metal complexes (group 11, IB): spectroscopic, thermal, kinetic measurements and biological activity. Spectrochim Acta Part A. 2007;68(5):1393–1405. doi: 10.1016/j.saa.2006.12.078. [DOI] [PubMed] [Google Scholar]
  • 152.Efthimiadou E. K., Psomas G., Sanakis Y., Katsaros N., Karaliota A. Metal complexes with the quinolone antibacterial agent N-propylnorfloxacin: Synthesis, structure and bioactivity. J Inorg Biochem. 2007;101(3):525–535. doi: 10.1016/j.jinorgbio.2006.11.020. [DOI] [PubMed] [Google Scholar]
  • 153.Efthimiadou E. K., Thomadaki H., Sanakis Y., Raptopoulou C. P., Katsaros N., Scorilas A., Karaliota A., Psomas G. Structure and biological properties of the copper(II) complex with the quinolone antibacterial drug N-propyl-norfloxacin and 2,20-bipyridine. J Inorg Biochem. 2007;101(1):64–73. doi: 10.1016/j.jinorgbio.2006.07.019. [DOI] [PubMed] [Google Scholar]
  • 154.Efthimiadou E. K., Katsaros N., Karaliota A., Psomas G. Mononuclear copper(II) complexes with quinolones and nitrogen-donor heterocyclic ligands: synthesis, characterization, biological activity and interaction with DNA. Inorg Chim Acta. 2007;360(15):4093–4102. doi: 10.1016/j.ica.2007.05.042. [DOI] [Google Scholar]
  • 155.Turel I., Golic L., Bukovec P., Gubina M. Antibacterial tests of Bismuth(III)-quinolone (ciprofloxacin, cf) compounds against helicobacter pylori and some other bacteria. Crystal structure of (cfH2)2[Bi2Cl10]·4H2O. J Inorg Biochem. 1998;71(1):53–60. doi: 10.1016/s0162-0134(98)10032-6. [DOI] [PubMed] [Google Scholar]
  • 156.López-Gresa M. P., Ortiz R., Perelló L., Latorre J., Liu-González M., García-granda S., Pérez-Priede M., Cantón E. Interactions of metal ions with two quinolone antimicrobial agents (cinoxacin and ciprofloxacin) spectroscopic and X-ray structural characterization. Antibacterial studies. J Inorg Biochem. 2002;92(1):65–74. doi: 10.1016/S0162-0134(02)00487-7. [DOI] [PubMed] [Google Scholar]
  • 157.Efthimiadou E. K., Sanakis Y., Katsarou M., Raptopoulou C. P., Karaliota A., Katsaros N., Psomas G. Neutral and cationic mononuclear copper(II) complexes with enrofloxacin: structure and biological activity. J Inorg Biochem. 2006;100(8):1378–1388. doi: 10.1016/j.jinorgbio.2006.03.013. [DOI] [PubMed] [Google Scholar]
  • 158.Efthimiadou E. K., Katsarou M. E., Karaliota A., Psomas G. Copper(II) complexes with sparfloxacin and nitrogen-donor heterocyclic ligands: Structure-activity relationship. J Inorg Biochem. 2008;102(4):910–920. doi: 10.1016/j.jinorgbio.2007.12.011. [DOI] [PubMed] [Google Scholar]
  • 159.Mondelli M., Bruné V., Borthagaray G., Ellena J., Nascimento O. R., Leite C. Q., Batista A. A., Torre M. H. New Ni(II)-sulfonamide complexes: synthesis, structural characterization and antibacterial properties. X-ray diffraction of [Ni(sulfisoxazole)2(H2O)4]·2H2O and [Ni(sulfapyridine)2]. J Inorg Biochem. 2008;102(2):285–292. doi: 10.1016/j.jinorgbio.2007.09.001. [DOI] [PubMed] [Google Scholar]
  • 160.Marques L. L., Oliveira G. M., Lang E. S., Campos M. M. A., Gris L. R. S. New gold(I) and silver(I) complexes of sulfamethoxazole: synthesis, X-ray structural characterization and microbiological activities of triphenylphosphine(sulfamethoxazolato-N2)gold(I) and (sulfamethoxazolato) silver(I) Inorg Chem Commun. 2007;10(9):1083–1087. doi: 10.1016/j.inoche.2007.06.005. [DOI] [Google Scholar]
  • 161.Chohan Z. H., Shaikh A. U., Naseer M. M. Metal-based isatin-bearing sulfonamides: Their synthesis, characterization and biological properties. Appl Organometal Chem. 2006;20(11):729–739. doi: 10.1002/aoc.1134. [DOI] [Google Scholar]
  • 162.Sharaby C. M. Synthesis, spectroscopic, thermal and antimicrobial studies of some novel metal complexes of Schiff base derived from [N1-(4-methoxy-1,2,5-thiadiazol-3-yl)sulfanilamide] and 2-thiophene carboxaldehyde. Spectrochim Acta Part A. 2007;66(4-5):1271–1278. doi: 10.1016/j.saa.2006.05.030. [DOI] [PubMed] [Google Scholar]
  • 163.Huang J., Cui Z. N., Li Y., Yang X. L. Bioactivities of copper complexes with schiff bases. Chin J Org Chem (in Chinese) 2008;28(4):598–604. [Google Scholar]
  • 164.Kumar K. N., Ramesh R. Synthesis, characterization, redox property and biological activity of Ru(II) carbonyl complexes containing O,N-donor ligands and heterocyclic bases. Spectrochim Acta Part A. 2004;60(12):2913–2918. doi: 10.1016/j.saa.2004.02.011. [DOI] [PubMed] [Google Scholar]
  • 165.Venkatachalam G., Ramesh R. Catalytic and biological activities of Ru(III) mixed ligand complexes containing N, O donor of 2-hydroxy-1-naphthylideneimines. Spectrochim Acta Part A. 2005;61(9):2081–2087. doi: 10.1016/j.saa.2004.08.008. [DOI] [PubMed] [Google Scholar]
  • 166.Daniel V. P., Murukan B., Kumari B. S., Mohanan K. Synthesis, spectroscopic characterization, electrochemical behaviour, reactivity and antibacterial activity of some transition metal complexes with 2-(N-salicylideneamino)-3-carboxyethyl-4,5-dimethylthiophene. Spectrochim Acta Part A. 2008;70(2):403–410. doi: 10.1016/j.saa.2007.11.003. [DOI] [PubMed] [Google Scholar]
  • 167.Abd-Elzaher M. M. Synthesis, characterization, and antimicrobial activity of cobalt(II), nickel(II), copper(II) and zinc(II) complexes with ferrocenyl Schiff bases containing a phenol moiety. Appl Organometa Chem. 2004;18(4):149–155. doi: 10.1002/aoc.608. [DOI] [Google Scholar]
  • 168.Singh B. K., Jetley U. K., Sharma R. K., Garg B. S. Synthesis, characterization and biological activity of complexes of 2-hydroxy-3, 5-dimethylaceto-phenoneoxime(HDMAOX) with copper(II), cobalt (II), nickel(II) and palladium(II) Spectrochimica Acta Part A. 2007;68(1):63–73. doi: 10.1016/j.saa.2006.11.001. [DOI] [PubMed] [Google Scholar]
  • 169.Prabhakaran R., Geetha A., Thilagavathi M., Karvembu R., Krishnan V., Bertagnolli H., Natarajan K. Synthesis, characterization, EXAFS investigation and antibacterial activities of new ruthenium(III) complexes containing tetradentate Schiff base. J Inorg Biochem. 2004;98(12):2131–2140. doi: 10.1016/j.jinorgbio.2004.09.020. [DOI] [PubMed] [Google Scholar]
  • 170.Bagihalli G. B., Avaji P. G., Patil S. A., Badami P. S. Synthesis, spectral characterization, in vitro antibacterial, antifungal and cytotoxic activities of Co(II), Ni(II) and Cu(II) complexes with 1,2,4-triazole Schiff bases. Eur J Med Chem. 2008;43(12):2639–2649. doi: 10.1016/j.ejmech.2008.02.013. [DOI] [PubMed] [Google Scholar]
  • 171.Singh K., Barwa M. S., Tyagi P. Synthesis, characterization and biological studies of Co(II), Ni(II), Cu(II) and Zn(II) complexes with bidentate Schiff bases derived by heterocyclic ketone. Eur J Med Chem. 2006;41(1):147–153. doi: 10.1016/j.ejmech.2005.06.006. [DOI] [PubMed] [Google Scholar]
  • 172.Singh K., Barwa M. S., Tyagi P. Synthesis and characterization of cobalt(II), nickel(II), copper(II) and zinc(II) complexes with Schiff base derived from 4-amino-3-mercapto-6-methyl-5-oxo-1,2,4-triazine. Eur J Med Chem. 2007;42(3):394–402. doi: 10.1016/j.ejmech.2006.10.016. [DOI] [PubMed] [Google Scholar]
  • 173.Kurtaran R., Yildirim L. T., Azaz A. D., Namli H., Atakol O. Synthesis, characterization, crystal structure and biological activity of a novel heterotetranuclear complex: [NiLPb(SCN)2(DMF)(H2O)]2, bis-{[μ-N, N′-bis(salicylidene)-1,3-propanediaminato-aqua-nickel(II)](thiocyan ato) (l-thiocyanato) (l-N,N-dimethylformamide)lead(II)} J Inorg Biochem. 2005;99(10):1937–1944. doi: 10.1016/j.jinorgbio.2005.05.016. [DOI] [PubMed] [Google Scholar]
  • 174.Yildirim L. T., Kurtaran R., Namli H., Azaz A. D., Atakol O. Synthesis, crystal structure and biological activity of two new heterotrinuclear thiocyanato bridged Cu(II)-Hg(II)-Cu(II) complexes. Polyhedron. 2007;26(15):4187–4194. doi: 10.1016/j.poly.2007.05.020. [DOI] [Google Scholar]
  • 175.Lv J., Liu T. T., Cai S. L., Wang X., Liu L., Wang Y. M. Synthesis, structure and biological activity of cobalt(II) and copper(II) complexes of valine-derived schiff bases. J Inorg Biochem. 2006;100(11):1888–1896. doi: 10.1016/j.jinorgbio.2006.07.014. [DOI] [PubMed] [Google Scholar]
  • 176.Chohan Z. H., Supuran C. T. Organometallic compounds with biologically active molecules: in vitro antibacterial and antifungal activity of some 1,1′-(dicarbohydrazono) ferrocenes and their cobalt(II), copper(II), nickel(II) and zinc(II) complexes. Appl Organometal Chem. 2005;19(12):1207–1214. doi: 10.1002/aoc.944. [DOI] [Google Scholar]
  • 177.Chohan Z. H., Khan K. M., Supuran C. T. Synthesis of antibacterial and antifungal cobalt(II), copper(II), nickel(II) and zinc(II) complexes with bis-(1,1’-disubstituted ferrocenyl)thiocarbohydrazone and bis-(1,1′-disubstituted ferrocenyl)carbohydrazone. Appl Organometal Chem. 2004;18(7):305–310. doi: 10.1002/aoc.620. [DOI] [Google Scholar]
  • 178.Chitrapriya N., Mahalingam V., Channels L. C., Zeller M., Fronczek F. R., Natarajan K. Novel Ru(II) oximato complexes with silent oxygen atom: synthesis, chemistry and biological activities. Inorg Chim Acta. 2008;361(9–10):2841–2850. doi: 10.1016/j.ica.2008.02.010. [DOI] [Google Scholar]
  • 179.El-Behery M., El-Twigry H. Synthesis, magnetic, spectral, and antimicrobial studies of Cu(II), Ni(II) Co(II), Fe(III), and UO2(II) complexes of a new Schiff base hydrazone derived from 7-chloro-4-hydrazinoquinoline. Spectrochimica Acta Part A. 2007;66(1):28–36. doi: 10.1016/j.saa.2006.02.017. [DOI] [PubMed] [Google Scholar]
  • 180.Özmen Ö. ü., Olgun G. Synthesis, characterization and antibacterial activityof new sulfonyl hydrazone derivatives and their nickel(II) complexes. Spectrochim Acta Part A. 2008;70(3):641–645. doi: 10.1016/j.saa.2007.08.012. [DOI] [PubMed] [Google Scholar]
  • 181.Rodríguez-Argüelles M. C., Mosquera-Vázquez S., Tourón-Touceda P., Sanmartiín-Matalobos J., Garca-Deibe A. M., Belicchi-Ferrari M., Pelosi G., Pelizzi C., Zani F. Complexes of 2-thiophenecarbonyl and isonicotinoyl hydrazones of 3-(N-methyl)isatin. A study of their antimicrobial activity. J Inorg Biochem. 2007;101(1):138–147. doi: 10.1016/j.jinorgbio.2006.09.004. [DOI] [PubMed] [Google Scholar]
  • 182.Mendes I. C., Moreira J. P., Mangrich A. S., Balena S. P., Rodrigues B. L., Beraldo H. Coordination to copper(II) strongly enhances the in vitro antimicrobial activity of pyridine-derived N(4)-tolyl thiosemicarbazones. Polyhedron. 2007;26(13):3263–3270. doi: 10.1016/j.poly.2007.03.002. [DOI] [Google Scholar]
  • 183.Nomiya K., Sekino K., Ishikawa M., Honda A., Yokoyama M., Kasuga N. C., Yokoyama H., Nakano S., Onodera K. Syntheses, crystal structures and antimicrobial activities of monomeric 8-coordinate, and dimeric and monomeric 7-coordinate bismuth(III) complexes with tridentate and pentadentate thiosemicarbazones and pentadentate semicarbazone ligands. J Inorg Biochem. 2004;98(4):601–615. doi: 10.1016/j.jinorgbio.2004.01.011. [DOI] [PubMed] [Google Scholar]
  • 184.Kannan S., Sivagamasundari M., Ramesh R., Liu Y. Ruthenium(II) carbonyl complexes of dehydroacetic acid thiosemicarbazone: synthesis, structure, light emission and biological activity. J Organomet Chem. 2008;693(13):2251–2257. doi: 10.1016/j.jorganchem.2008.03.023. [DOI] [Google Scholar]
  • 185.John R. P., Sreekanth A., Rajakannan V., Ajith T. A., Kurup M. R. P. New copper(II) complexes of 2-hydroxyacetophenone N(4)-substituted thiosemicarbazones and polypyridyl co-ligands: Structural, electrochemical and antimicrobial studies. Polyhedron. 2004;23(16):2549–2559. doi: 10.1016/j.poly.2004.09.004. [DOI] [Google Scholar]
  • 186.Khan S A, Yusuf M. Synthesis, spectral studies and in vitro antibacterial activity of steroidal thiosemicarbazone and their palladium (Pd(II)) complexes. Eur J Med Chem, 2009, doi:10.1016/j.ejmech [DOI] [PubMed]
  • 187.Rodríguez-Argüelles M. C., López-Silva E. C., Sanmartín J., Pelagatti P., Zani F. Copper complexes of imidazole-2-, pyrrole-2- and indol-3-carbaldehyde thiosemicarbazones: Inhibitory activity against fungi and bacteria. J Inorg Biochem. 2005;99(11):2231–2239. doi: 10.1016/j.jinorgbio.2005.07.018. [DOI] [PubMed] [Google Scholar]
  • 188.Bacchi A., Carcelli M., Pelagatti P., Pelizzi G., Rodriguez-Arguelles M. C., Rogolino D., Solinas C., Zani d. F. Antimicrobial and mutagenic properties of organotin(IV) complexes with isatin and N-alkylisatin bisthiocarbonohydrazones. J Inorg Biochem. 2005;99(2):397–408. doi: 10.1016/j.jinorgbio.2004.10.008. [DOI] [PubMed] [Google Scholar]
  • 189.Li Q. X., Tang H. A., Li Y. Z., Wang M., Wang L. F., Xia C. G. Synthesis, characterization, and antibacterial activity of novel Mn(II), Co(II), Ni(II), Cu(II), and Zn(II) complexes with vitamin K3-thiosemicarbazone. J Inorg Biochem. 2000;78(2):167–174. doi: 10.1016/S0162-0134(99)00226-3. [DOI] [PubMed] [Google Scholar]
  • 190.Zhang Y., Xiao X., Deng P. X., Huang Q. M., Pan Z. Q., Chen Z. P. Synthesis and antibacterial activity of β-substituted metalporphyrins of 1-naphthol. J Wuhan Inst Tech (in Chinese) 2008;30(4):8–11. [Google Scholar]
  • 191.Sreedaran S., Bharathi K. S., Rahiman A. K., Rajesh K., Nirmala G., Jagadish L., Kaviyarasan V., Narayanan V. Synthesis, electrochemical, catalytic and antimicrobial activities of novel unsymmetrical macrocyclic dicompartmental binuclear nickel(II) complexes. Polyhedron. 2008;27(7):1867–1874. doi: 10.1016/j.poly.2008.02.022. [DOI] [Google Scholar]
  • 192.Singh D P, Kumar R, Singh J. Synthesis and spectroscopic studies of biologically active compounds derived from oxalyldihydrazide and benzil, and their Cr(III), Fe(III) and Mn(III) complexes. Eur J Med Chem, 2009, doi:10.1016/j.ejmech.2008.03.007 (in press) [DOI] [PubMed]
  • 193.Reddy P. M., Prasad A. V. S. S., Shanker K., Ravinder V. Synthesis, spectral studies and antibacterial activity of novel macrocyclic Co(II) compounds. Spectrochim Acta Part A. 2007;68(3):1000–1006. doi: 10.1016/j.saa.2007.03.002. [DOI] [PubMed] [Google Scholar]
  • 194.Chandra S. Sangeetika. Spectroscopic, redox and biological activities of transition metal complexes with one donor macrocyclic ligand derived from semicarbazide and thiodiglycolic acid. Spectrochim Acta Part A. 2004;60(8):2153–2162. doi: 10.1016/j.saa.2003.09.027. [DOI] [PubMed] [Google Scholar]
  • 195.Shakir M., Azim Y., Chishti H. T. N., Parveen S. Synthesis, characterization of complexes of Co(II), Ni(II), Cu(II) and Zn(II) with 12-membered Schiff base tetraazamacrocyclic ligand and the study of their antimicrobial and reducing power. Spectrochim Acta Part A. 2006;65(2):490–496. doi: 10.1016/j.saa.2005.11.029. [DOI] [PubMed] [Google Scholar]
  • 196.Singh A P, Kaushik N K, Verma A K, Hundal G, Gupta R. Synthesis, structure and biological activity of copper(II) complexes of 4-(2-pyridylmethyl)-1,7-dimethyl-1,4,7-triazonane-2,6-dione and 4-(2-pyridylethyl)-1,7-dimethyl-1,4,7-triazonane-2,6-dione. Eur J Med Chem, 2009, doi:10.1016/j.ejmech.2008.07.029 (in press) [DOI] [PubMed]
  • 197.Roy T. G., Hazari S. K. S., Dey B. K., Miah H. A., Olbrich F., Rehder D. Synthesis and antimicrobial activities of isomers of N(4), N(II)-dimethyl-3,5,7,7,10,12,14,14-octamethyl-1,4,8,11-tetraazacycl o tetradecane and their nickel(II) complexes. Inorg Chem. 2007;46(13):5372–5380. doi: 10.1021/ic061700t. [DOI] [PubMed] [Google Scholar]
  • 198.Khanmohammadi H., Arabahmadi R., Abnosi M. H., Khavasi H. R. Synthesis, crystal structure, spectral and biological studies of CuII-MII(M = Zn and Pb)heterodinuclear complexes of new phenol-based macrocyclic ligands. Polyhedron. 2007;26(17):4963–4970. doi: 10.1016/j.poly.2007.07.018. [DOI] [Google Scholar]
  • 199.Guerra W., Azevedo E. A., Monteiro A. R. S., Bucciarelli-Rodriguez M., Chartone-Souza E., Nascimento A. M. A., Fontes A. P. S., Moyec L. L., Pereira-Maia E. C., Chartone-Souza E. Synthesis, characterization, and antibacterial activity of three palladium(II) complexes of tetracyclines. J Inorg Biochem. 2005;99(12):2348–2354. doi: 10.1016/j.jinorgbio.2005.09.001. [DOI] [PubMed] [Google Scholar]
  • 200.Refat M. S. Complexes of uranyl(II), vanadyl(II) and zirconyl(II) with orotic acid “vitamin B13”: Synthesis, spectroscopic, thermal studies and antibacterial activity. J Mol Struct. 2007;842(1-3):24–37. doi: 10.1016/j.molstruc.2006.12.006. [DOI] [Google Scholar]
  • 201.Kumar R. S., Arunachalam S. DNA binding and antimicrobial studies of some polyethyleneimine-copper(II) complex samples containing 1,10-phenanthroline and L-theronine as co-ligands. Polyhedron. 2007;26(13):3255–3262. doi: 10.1016/j.poly.2007.03.001. [DOI] [Google Scholar]
  • 202.Muthukumar M., Viswanathamurthi P., Natarajan K. Synthesis and spectral characterization of 2′-hydroxy chalconate complexes of ruthenium(II) and their catalytic and biological applications. Spectrochimica Acta Part A. 2008;70(5):1222–1226. doi: 10.1016/j.saa.2007.10.043. [DOI] [PubMed] [Google Scholar]
  • 203.Rodríguez-Fernández E., Manzano J. L., Benito J. J., Hermosa R., Monte E., Criado J. J. Thiourea, triazole and thiadiazine compounds and their metal complexes as antifungal agents. J Inorg Biochem. 2005;99(8):1558–1572. doi: 10.1016/j.jinorgbio.2005.05.004. [DOI] [PubMed] [Google Scholar]
  • 204.Mi J. L., Zhou C. H., Bai X. Advances in triazole antimicrobial agents. Chin J Antibiotics (in Chinese) 2007;32(10):587–593. [Google Scholar]
  • 205.Rowan R., Tallon T., Sheahan A. M., Curran R., McCann M., Kavanagh K., Devereux M., McKee V. ’silver bullets’ in antimicrobial chemotherapy: Synthesis, characterisation and biological screening of some new Ag(II)-containing imidazole complexes. Polyhedron. 2006;25(8):1771–1778. doi: 10.1016/j.poly.2005.11.021. [DOI] [Google Scholar]
  • 206.McCann M., Coyle B., Briody J., Bass F., O’Gorman N., Devereux M., Kavanagh K., McKee V. Synthesis and antimicrobial activity of (Z)-3-(1H-imidazol-1-yl)-2-phenylpropenenitrile and its metal complexes: X-ray crystal structures of the Zn(II) and Ag(II) complexes. Polyhedron. 2003;22(12):1595–1601. doi: 10.1016/S0277-5387(03)00284-5. [DOI] [Google Scholar]
  • 207.Mashaly M. M., El-Shafiy H. F., El-Maraghy S. B., Habib H. A. Synthesis, properties and thermal studies of oxorhenium(II) complexes with 3-hydrazino-5,6-diphenyl-1,2,4-triazine, benzimidazolethione and 2-hydrazinobenzimidazole mixed ligand complexes, pyrolytical products and biological activity. Spectrochim Acta Part A. 2005;61(8):1853–1869. doi: 10.1016/j.saa.2004.06.056. [DOI] [PubMed] [Google Scholar]
  • 208.Mastrolorenzo A., Scozzafava A., Supuran C. T. Antifungal activity of silver and zinc complexes of sulfadrug derivatives incorporating arylsulfonylureido moieties. Eur J Pharmaceu Sci. 2000;11(2):99–107. doi: 10.1016/S0928-0987(00)00093-2. [DOI] [PubMed] [Google Scholar]
  • 209.Bellú S., Hure E., Trapé M., Trossero C., Molina G., Drogo C., Williams P. A. M., Atria A. M., Acevedo J. C. M., Zacchino S., Sortino M., Campagnoli D., Rizzotto M. Synthesis, structure and antifungal properties of Co(II)-sulfathiazolate complexes. Polyhedron. 2005;24(4):501–509. doi: 10.1016/j.poly.2004.12.017. [DOI] [Google Scholar]
  • 210.Creaven B. S., Egan D. A., Karcz D., Kavanagh K., McCann M., Mahon M., Noble A., Thati B., Walsh M. Synthesis, characterisation and antimicrobial activity of copper(II) and manganese(II) complexes of coumarin-6,7-dioxyacetic acid (cdoaH2) and 4-methylcoumarin-6,7-dioxyacetic acid (4-MecdoaH2): X-ray crystal structures of [Cu(cdoa)-(phen)2]·8.8H2O and [Cu(4-Mecdoa)(phen)2]·13H2O (phen=1,10-phenanthroline) J Inorg Biochem. 2007;101(8):1108–1119. doi: 10.1016/j.jinorgbio.2007.04.010. [DOI] [PubMed] [Google Scholar]
  • 211.How F. N. F., Crouse K. A., Tahir M. I. M., Tarafder M. T. H., Cowley A. R. Synthesis, characterization and biological studies of S-benzyl-β-N-(benzoyl) dithiocarbazate and its metal complexes. Polyhedron. 2008;27(15):3325–3329. doi: 10.1016/j.poly.2008.07.022. [DOI] [Google Scholar]
  • 212.Devereux M., McCann M., Shea D. O., Kelly R., Egan D., Deegan C., Kavanagh K., McKee V., Finn G. Synthesis, antimicrobial activity and chemotherapeutic potential of inorganic derivatives of 2-(4′-thiazolyl) benzimidazole{thiabendazole}: X-ray crystal structures of [Cu(TBZH)2Cl]Cl·H2O·EtOH and TBZH2NO3 (TBZH = thiabendazole) J Inorg Biochem. 2004;98(6):1023–1031. doi: 10.1016/j.jinorgbio.2004.02.020. [DOI] [PubMed] [Google Scholar]
  • 213.Hothi H. S., Makkar A., Sharma J. R., Manrao M. R. Synthesis and antifungal potential of Co(II) complexes of 1-(2′-hydroxyphenyl) ethylideneanilines. Eur J Med Chem. 2006;41(2):253–255. doi: 10.1016/j.ejmech.2005.07.016. [DOI] [PubMed] [Google Scholar]
  • 214.Singh V. P., Katiyar A. Synthesis, spectral characterization and antimicrobial activity of some transition metal(II) complexes with acetone p-amino acetophenone benzoylhydrazone. Pesticide Biochem Physiol. 2008;92(1):8–14. doi: 10.1016/j.pestbp.2008.04.003. [DOI] [Google Scholar]
  • 215.Jouada E. M., Larcherb G., Allain M., Riou A., Boueta G. M., Khan M. A., Thanh X. D. Synthesis, structure and biological activity of nickel(II) complexes of 5-methyl-2-furfural thiosemicarbazone. J Inorg Biochem. 2001;86(2):565–571. doi: 10.1016/S0162-0134(01)00220-3. [DOI] [PubMed] [Google Scholar]
  • 216.Ali M. A., Mirza A. H., Hossain A. M. S., Nazimuddin M. Synthesis, characterization, antifungal properties and X-ray crystal structures of five- and six-coordinate copper(II) complexes of the 6-methyl-2-formylpyridine 4N-dimethylthiosemicarbazone. Polyhedron. 2001;20(9–10):1045–1052. doi: 10.1016/S0277-5387(01)00724-0. [DOI] [Google Scholar]
  • 217.Loginova N. V., Koval’chuk T. V., Zheldakova R. A., Chernyavskaya A. A., Osipovich N. P., Glushonok G. K., Polozov G. I., Povalishev V. N., Sorokin V. L., Shadyro O. I. Synthesis, characterization and antifungal activity of copper (II) complexes of sterically hindered o-diphenol derivatives. Polyhedron. 2006;25(18):3603–3610. doi: 10.1016/j.poly.2006.07.015. [DOI] [Google Scholar]
  • 218.Loginova N. V., Koval’chuk T. V., Polozov G. I., Osipovich N. P., Rytik P. G., Kucherov I. I., Chernyavskaya A. A., Sorokin V. L., Shadyro O. I. Synthesis, characterization, antifungal and anti-HIV activities of metal(II) complexes of 4,6-di-tert-butyl-3-[(2-hydroxyethyl)thio] benzene-1,2-diol. Eur J Med Chem. 2008;43(7):1536–1542. doi: 10.1016/j.ejmech.2007.09.024. [DOI] [PubMed] [Google Scholar]
  • 219.Bottari B., Maccari R., Monforte F., Ottanà R., Rotondo E., Vigorita M. G. Isoniazid-related copper(II) and nickel(II) complexes with antimycobacterial in vitro activity. Part 9. Bioorg Med Chem Lett. 2000;10(7):657–660. doi: 10.1016/S0960-894X(00)00058-5. [DOI] [PubMed] [Google Scholar]
  • 220.Maccari R., Ottanà R., Bottari B., Rotondo E., Vigorita M. G. In vitro advanced antimycobacterial screening of cobalt(II) and copper(II) complexes of fluorinated isonicotinoylhydrazones. Bioorg Med Chem Lett. 2004;14(23):5731–5733. doi: 10.1016/j.bmcl.2004.09.052. [DOI] [PubMed] [Google Scholar]
  • 221.Bottari B., Maccari R., Monforte F., Ottanà R., Vigorita M. G., Bruno G., Nicolò F., Rotondo A., Rotondo E. Nickel(II) 2,6-diacetylpyridine bis(isonicotinoylhydrazonate) and bis(benzoylhydrazonate) complexes: Structure and antimycobacterial evaluation. Part XI. Bioorg Med Chem. 2001;9(8):2203–2211. doi: 10.1016/S0968-0896(01)00133-X. [DOI] [PubMed] [Google Scholar]
  • 222.Sandbhor U., Padhye S., Billington D., Rathbone D., Franzblau S., Anson C. E., Powell A. K. Metal complexes of carboxamidrazone analogs as antitubercular agents 1. Synthesis, X-ray crystal-structures, spectroscopic properties and antimycobacterial activity against mycobacterium tuberculosis H37Rv. J Inorg Biochem. 2002;90(3–4):127–136. doi: 10.1016/S0162-0134(02)00406-3. [DOI] [PubMed] [Google Scholar]
  • 223.Saha D. K., Padhye S., Anson C. E., Powell A. K. Hydrothermal synthesis, crystal structure, spectroscopy, electrochemistry and antimycobacterial evaluation of the copper (II) ciprofloxacin complex: [Cu(cf)2-(BF4)2]·6H2O. Inorg Chem Commun. 2002;5(12):1022–1027. doi: 10.1016/S1387-7003(02)00635-4. [DOI] [Google Scholar]
  • 224.Saha D. K., Sandbhor U., Shirisha K., Padhye S., Deobagkar D., Anson C. E., Powell A. K. A novel mixed-ligand antimycobacterial dimeric copper complex of ciprofloxacin and phenanthroline. Bioorg Med Chem Lett. 2004;14(12):3027–3032. doi: 10.1016/j.bmcl.2004.04.043. [DOI] [PubMed] [Google Scholar]
  • 225.Razafimahefa D., Ralambomanana D. A., Hammouche L., Pélinski L., Lauvagie S., Bebear C., Brocard J., Maugein J. Synthesis and antimycobacterial activity of ferrocenyl ethambutol analogues and ferrocenyl diamines. Bioorg Med Chem Lett. 2005;15(9):2301–2303. doi: 10.1016/j.bmcl.2005.03.004. [DOI] [PubMed] [Google Scholar]
  • 226.Cuin A., Massabni A. C., Leite C. Q. F., Sato D. N., Neves A., Szpoganicz B., Silva M. S., Bortoluzzi A. J. Synthesis, X-ray structure and antimycobacterial activity of silver complexes with α-hydroxycarboxylic acids. J Inorg Biochem. 2007;101(2):291–296. doi: 10.1016/j.jinorgbio.2006.10.001. [DOI] [PubMed] [Google Scholar]
  • 227.Cavicchioli M., Leite C. Q. F., Sato D. N., Massabni A. C. Synthesis, characterization and antimycobacterial activity of Ag(I)-aspartame, Ag(I)-saccharin and Ag(I)-cyclamate complexes. Arch Pharm Chem Life Sci. 2007;340(10):538–542. doi: 10.1002/ardp.200700040. [DOI] [PubMed] [Google Scholar]
  • 228.Ventura C. A., Giannone I., Musumeci T., Pignatello R., Ragni L., Landolfi C., Milanese C., Paolino D., Puglisi G. Physico-chemical characterization of disoxaril-dimethyl-β-cyclodextrin inclusion complex and in vitro permeation studies. Eur J Med Chem. 2006;41(2):233–240. doi: 10.1016/j.ejmech.2005.11.002. [DOI] [PubMed] [Google Scholar]
  • 229.Liang X. Y., Sadler P. J. Cyclam complexes and their applications in medicine. Chem Soc Rev. 2004;33(4):246–266. doi: 10.1039/b313659k. [DOI] [PubMed] [Google Scholar]
  • 230.Turel I., Bukovec N., Goodgame M., Williams D. J. Synthesis and characterization of copper(II) coordination compounds with acyclovir: crystal structure of triaquabis [9-{(2-hydroxyethoxy) methyl}guanine]copper(II)nitrate(V)hydrate. Polyhedron. 1997;16(10):1701–1706. doi: 10.1016/S0277-5387(96)00466-4. [DOI] [Google Scholar]
  • 231.Turel I., Andersen B., Sletten E., White A. J. P., Williams D. J. New studies in the copper(II) acyclovir (acv) system. NMR relaxation studies and the X-ray crystal structure of [Cu(acv)2(H2O)2](NO3)2. Polyhedron. 1998;17(23–24):4195–4201. doi: 10.1016/S0277-5387(98)00229-0. [DOI] [Google Scholar]
  • 232.García-Raso, Fiol J. J., Bádenas F., Cons R., Terrón, Quirós M. Synthesis and structural characteristics of metal-acyclovir (ACV) complexes: [Ni(or Co)(ACV)2 (H2O)4]Cl2·2ACV, [Zn(ACV)Cl2-(H2O)], [Cd(ACV)Cl2] H2O and [{Hg(ACV)Cl22}x] Recognition of acyclovir by Ni-ACV. J Chem Soc Dalton Trans. 1999;2:167–173. [Google Scholar]
  • 233.Panagiotopoulou A., Katsaros N., Masi N. G. D., Natile G. Synthesis and characterisation of platinum(II) complexes with the antiviral agents ftorafur and furavir. Inorg Chim Acta. 2001;325(1–2):73–78. doi: 10.1016/S0020-1693(01)00629-6. [DOI] [Google Scholar]
  • 234.Wooley P. H., Whalen J. D. The influence of superoxide scavenging compound CTC 23 on type. collagen-induced arthritis in mice. Agents Actions. 1992;35(3–4):273–279. doi: 10.1007/BF01997511. [DOI] [PubMed] [Google Scholar]
  • 235.Schwartz J. A., Lium E. K., Verstein S. J. S. Herpes simplex virus type I entry is inhibited by the cobalt chelate complex CTC-96. J Virology. 2001;75(9):4117–4128. doi: 10.1128/JVI.75.9.4117-4128.2001. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 236.Delehanty J. B., Bongard J. E., Thach D. C., Knight D. A., Hickey T. E., Chang E. L. Antiviral properties of cobalt(III)-complexes. Bioorg Med Chem. 2008;16(2):830–837. doi: 10.1016/j.bmc.2007.10.022. [DOI] [PubMed] [Google Scholar]
  • 237.Allardyce C. S., Dyson P. J., Ellis D. J., Salter P. A., Scopelliti R. Synthesis and characterisation of some water soluble ruthenium(II)-arene complexes and an investigation of their antibiotic and antiviral properties. J Organomet Chem. 2003;668(1-2):35–42. doi: 10.1016/S0022-328X(02)01926-5. [DOI] [Google Scholar]
  • 238.Koester L. S., Bertuol J. B., Groch K. R., Xavier C. R., Moellerke R., Mayorga P., Costa T. D., Bassani V. L. Bioavailability of carbamazepine: β-cyclodextrin complex in beagle dogs from hydroxypropylmethylcellulose matrix tablets. Eur J Pharm Sci. 2004;22(2-3):201–207. doi: 10.1016/j.ejps.2004.03.010. [DOI] [PubMed] [Google Scholar]
  • 239.Beraldo H., Sinisterra R. D., Teixeira L. R., Vieira R. P., Doretto M. C. An effective anticonvulsant prepared following a host-guest strategy that uses hydroxypropyl-β-cyclodextrin and benzaldehyde semicarbazone. Biochem Biophys Res Commun. 2002;296(2):241–246. doi: 10.1016/S0006-291X(02)00865-3. [DOI] [PubMed] [Google Scholar]
  • 240.Viossat B., Daran J. C., Savouret G., Morgant G., Greenaway F. T., Dung N. H., Pham-Tran V. A., Sorenson J. R. J. Low-temperature (180 K) crystal structure, electron paramagnetic resonance spectroscopy, and propitious anticonvulsant activities of Cu2II(aspirinate)4(DMF)2 and other Cu2II.(aspirinate)4 chelates. J Inorg Biochem. 2003;96(2-3):375–385. doi: 10.1016/S0162-0134(03)00153-3. [DOI] [PubMed] [Google Scholar]
  • 241.Viossat B., Greenaway F. T., Morgant G., Daran J. C., Dung N. H., Sorenson J. R. J. Low-temperature (180 K) crystal structures of tetrakis-μ-(niflumato)di(aqua)dicopper(II) N,N-dimethylformamide and N,N-dimethylacetamide solvates, their EPR properties, and anticonvulsant activities of these and other ternary binuclear copper (II)niflumate complexes. J Inorg Biochem. 2005;99(2):355–367. doi: 10.1016/j.jinorgbio.2004.10.001. [DOI] [PubMed] [Google Scholar]
  • 242.Lemoine P., Viossat B., Dung N. H., Tomas A., Morgant G., Greenaway F. T., Sorenson J. R. J. Synthesis, crystal structures, and anti-convulsant activities of ternary [ZnII(3,5-dIIsopropylsalicylate)2], [ZnII(salicylate)2] and [ZnII(aspirinate)2] complexes. J Inorg Biochem. 2004;98(11):1734–1749. doi: 10.1016/j.jinorgbio.2004.07.010. [DOI] [PubMed] [Google Scholar]
  • 243.d’Angelo J., Morgant G., Ghermani N. E., Desmaële D., Fraisse B., Bonhomme F., Dichi E., Sghaier M., Li Y. L., Journaux Y., Sorenson J. R. J. Crystal structures and physico-chemical properties of Zn(II) and Co(II) tetraaqua(3-nitro-4-hydroxybenzoato) complexes: their anticonvulsant activities as well as related (5-nitrosalicylato)-metal complexes. Polyhedron. 2008;27(2):537–546. doi: 10.1016/j.poly.2007.10.006. [DOI] [Google Scholar]
  • 244.Wang Z., Hirayama F., Uekama K. In-vivo and in-vitro evaluations of a modified-release oral dosage form of nifedipine by hybridization of hydroxypropyl-beta-cyclodextrin and hydroxypropylcelluloses in dogs. J Pharm Pharmacol. 1994;46(6):505–507. doi: 10.1111/j.2042-7158.1994.tb03836.x. [DOI] [PubMed] [Google Scholar]
  • 245.Ikeda Y., Kimura K., Hirayama F., Arima H., Uekama K. Controlled release of a water-soluble drug, captopril, by a combination of hydrophilic and hydrophobic cyclodextrin derivatives. J Controlled Release. 2000;66(2–3):271–280. doi: 10.1016/S0168-3659(99)00286-2. [DOI] [PubMed] [Google Scholar]
  • 246.Kopecky F., Kopecka B., Kaclik P. Dissolution of nimodipine in an aqueous solution of hydroxyethyl-beta-cyclodextrin and a review of solubility of nimodipine with cyclodextrins. Ceska Slov Farm. 2003;52(1):33–38. [PubMed] [Google Scholar]
  • 247.Fernandes C. M., Veiga F. J. B. Effect of the hydrophobic nature of triacetyl-β-cyclodextrin on the complexation with nicardipine hydrochloride: physicochemical and dissolution properties of the kneaded and spray-dried complexes. Chem Pharm Bull. 2002;50(12):1597–1602. doi: 10.1248/cpb.50.1597. [DOI] [PubMed] [Google Scholar]
  • 248.Nagase Y., Hirata M., Wada K., Arima H., Hirayama F., Irie T., Kikuchi M., Uekama K. Improvement of some pharmaceutical properties of DY-9760e by sulfobutyl ether β-cyclodextrin. Int J Pharm. 2001;229(1–2):163–172. doi: 10.1016/S0378-5173(01)00851-1. [DOI] [PubMed] [Google Scholar]
  • 249.Nagase Y., Arima H., Wada K., Sugawara T., Satoh H., Hirayama F., Uekama K. Inhibitory effect of sulfobutyl ether β-cyclodextrin on DY-9760e-induced cellular damage: In vitro and in vivo studies. J Pharm Sci. 2003;92(12):2466–2474. doi: 10.1002/jps.10517. [DOI] [PubMed] [Google Scholar]
  • 250.Judenhofer M. S., Wehrl H. F., Newport D. F., Catana C., Siegel S. B., Becker M., Thielscher A., Kneilling M., Lichy M. P., Eichner M., Klingel K., Reischl G., Widmaier S., Röcken M., Nutt R. E., Machulla H. J., Uludag K., Cherry S. R., Claussen C. D., Pichler B. J. Simultaneous PET-MRI: A new approach for functional and morphological imaging. Nat Med. 2008;14(4):459–465. doi: 10.1038/nm1700. [DOI] [PubMed] [Google Scholar]
  • 251.Caravan P., Ellison J. J., McMurry T. J., Lauffer R. B. Gadolinium (II) chelates as MRI contrast agents: Structure, dynamics, and applications. Chem Rev. 1999;99(9):2293–2352. doi: 10.1021/cr980440x. [DOI] [PubMed] [Google Scholar]
  • 252.Parker D., Dickins R. S., Puschmann H., Crossland C., Howard J. A. K. Being Excited by lanthanide coordination complexes: Aqua species, chirality, excited-state chemistry, and exchange dynamics. Chem Rev. 2002;102(6):1977–2010. doi: 10.1021/cr010452+. [DOI] [PubMed] [Google Scholar]
  • 253.Bellin M. F. MR contrast agents, the old and the new. Eur J Radiol. 2006;60(3):314–323. doi: 10.1016/j.ejrad.2006.06.021. [DOI] [PubMed] [Google Scholar]
  • 254.Aime S., Crich S. G., Gianolio E., Giovenzana G. B., Tei L., Terreno E. High sensitivity lanthanide(III) based probes for MR-medical imaging. Coord Chem Rev. 2006;250(11–12):1562–1579. doi: 10.1016/j.ccr.2006.03.015. [DOI] [Google Scholar]
  • 255.Lattuada L., Demattio S., Vincenzi V., Cabella C., Visigalli M., Aime S., Crich S. G., Gianolio E. Magnetic resonance imaging of tumor cells by targeting the amino acid transport system. Bioorg Med Chem Lett. 2006;16(15):4111–4114. doi: 10.1016/j.bmcl.2006.04.081. [DOI] [PubMed] [Google Scholar]
  • 256.Hermann P., Kotek J., Kubícek V., Lukš I. Gadolinium(III) complexes as MRI contrast agents: ligand design and properties of the complexes. Dalton Trans. 2008;23:3027–3047. doi: 10.1039/b719704g. [DOI] [PubMed] [Google Scholar]
  • 257.Yan G. P., Robinson L., Hogg P. Magnetic resonance imaging contrast agents: Overview and perspectives. Radiography. 2007;13(1):e5–e19. doi: 10.1016/j.radi.2006.07.005. [DOI] [Google Scholar]
  • 258.Feng J. H., Sun G. Y., Pei F. K., Liu M. L. Comparison between Gd-DTPA and several bisamide derivatives as potential MRI contrast agents. Bioorg Med Chem. 2003;11(15):3359–3366. doi: 10.1016/S0968-0896(03)00263-3. [DOI] [PubMed] [Google Scholar]
  • 259.Caravan P., Cloutier N. J., Greenfield M. T., McDermid S. A., Dunham S. U., Bulte J. W., Amedio M. J. C., Looby J. R. J., Supkowski R. M., Horrocks W. D., McMurry J. T. J., Lauffer R. B. The interaction of MS-325 with human serum albumin and its effect on proton relaxation rates. J Am Chem Soc. 2002;124(12):3152–3162. doi: 10.1021/ja017168k. [DOI] [PubMed] [Google Scholar]
  • 260.Chong H. S., Garmestani K., Bryant L. H., Milenic J. D. E., Overstreet T., Birch N., Le T., Brady E. D., Brechbiel M. W. Synthesis and evaluation of novel macrocyclic and acyclic ligands as contrast enhancement agents for magnetic resonance imaging. J Med Chem. 2006;49(6):2055–2062. doi: 10.1021/jm051009k. [DOI] [PubMed] [Google Scholar]
  • 261.Corot C., Port M., Raynal I., Dencausse A., Schaefer M., Rousseaux O., Simonot C., Devoldere L., Lin J., Foulon M., Bourrinet P., Bonnemain B., Meyer D. Physical, chemical, and biological evaluations of P760: A new gadolinium complex characterized by a low rate of interstitial diffusion. J Magn Reson Imaging. 2000;11(2):182–191. doi: 10.1002/(SICI)1522-2586(200002)11:2<182::AID-JMRI16>3.0.CO;2-5. [DOI] [PubMed] [Google Scholar]
  • 262.Delgado R., Félix V., Lima L. M. P., Price D. W. Metal complexes of cyclen and cyclam derivatives useful for medical applications: A discussion based on thermodynamic stability constants and structural data. Dalton Trans. 2007;26:2734–2745. doi: 10.1039/b704360k. [DOI] [PubMed] [Google Scholar]
  • 263.Hovland R., Gløgård C., Aasen A. J., Klaveness J. Gadolinium DO3A derivatives mimicking phospholipids: preparation and in vitro evaluation as pH responsive MRI contrast agents. J Chem Soc, Perkin Trans. 2001;2(6):929–933. [Google Scholar]
  • 264.Xiang Q. X., Xia C. Q., Yu X. Q., Zhang L. Q., Xie R. G. Recent advances in macrocyclic polyamines and their metal complexes. Chin J Org Chem (in Chinese) 2004;24(9):981–986. [Google Scholar]
  • 265.Chong H. S., Song H. A., Ma X., Milenic D. E., Brady E. D., Lim S. Y., Lee H. S., Baidoo K. E., Cheng D. F., Brechbiel M. W. Novel bimodal bifunctional ligands for adioimmunotherapy and targeted MRI. Bioconjugate Chem. 2008;19(7):1439–1447. doi: 10.1021/bc800050x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 266.Cavagna F. M., Lorusso V., Anelli P. L., Maggioni F., de -Haën C. Preclinical profile and clinical potential of gadocoletic acid trisodium salt (B22956/1), A new intravascular contrast medium for MRI. Acad Radiol. 2002;9(2):491–494. doi: 10.1016/S1076-6332(03)80273-8. [DOI] [PubMed] [Google Scholar]
  • 267.Rudovský J., Botta M., Hermann P., Hardcastle K. I., Lukey I., Aime S. PAMAM dendrimeric conjugates with a Gd-DOTA phosphinate derivative and their adducts with polyaminoacids: The interplay of global motion, internal rotation, and fast water exchange. Bioconjugate Chem. 2006;17(4):975–987. doi: 10.1021/bc060149l. [DOI] [PubMed] [Google Scholar]
  • 268.Battistini E., Gianolio E., Gref R., Couvreur P., Fuzerova S., Othman M., Aime S., Badet B., Durand P. High-relaxivity magnetic resonance imaging (MRI) contrast agent based on supramolecular assembly between a gadolinium chelate, a modified dextran, and poly-β-cyclodextrin. Chem Eur J. 2008;14(15):4551–4561. doi: 10.1002/chem.200701587. [DOI] [PubMed] [Google Scholar]
  • 269.Khafagy E. S., Morishita M., Onuki Y., Takayama K. Current challenges in non-invasive insulin delivery systems: Acomparative review. Adv Drug Deliv Rev. 2007;59(15):1521–1546. doi: 10.1016/j.addr.2007.08.019. [DOI] [PubMed] [Google Scholar]
  • 270.Sajeesh S., Sharma C. P. Cyclodextrin-insulin complex encapsulated polymethacrylic acid based nanoparticles for oral insulin delivery. Int J Pharm. 2006;325(1–2):147–154. doi: 10.1016/j.ijpharm.2006.06.019. [DOI] [PubMed] [Google Scholar]
  • 271.Higashi T., Hirayama F., Misumi S., Arima H., Uekama K. Design and evaluation of polypseudorotaxanes of pegylated insulin with cyclodextrins as sustained release system. Biomaterials. 2008;29(28):3866–3871. doi: 10.1016/j.biomaterials.2008.06.019. [DOI] [PubMed] [Google Scholar]
  • 272.Suihko E., Korhonen O., Järvinen T., Ketolainen J., Jarho P., Laine E., Paronen P. Complexation with tolbutamide modifies the physicochemical and tableting properties of hydroxypropyl-β-cyclodextrin. Int J Pharm. 2001;215(1–2):137–145. doi: 10.1016/S0378-5173(00)00682-7. [DOI] [PubMed] [Google Scholar]
  • 273.Guiotoku M., Silva F. R. M. B., Azzolini J. C., Mercê A. L. R., Mangrich A. S., Sala L. F., Szpoganicz B. Monosaccharides and the VO(IV) metal ion: equilibrium, thermal studies and hypoglycemic effect. Polyhedron. 2007;26(6):1269–1276. doi: 10.1016/j.poly.2006.10.032. [DOI] [Google Scholar]
  • 274.Hidetoshi A., Kiyokazu Y., Kouzou M., Tetsumi I., Fumitoshi H., Kaneto U. Comparative studies of the enhancing effects of cyclodextrins on the solubility and oral bioavailability of tacrolimus in rats. J Pharm Sci. 2001;90(6):690–701. doi: 10.1002/jps.1025. [DOI] [PubMed] [Google Scholar]
  • 275.Bom A., Bradley M., Cameron K., Clark J. K., Van E. J., Feilden H., Maclean E. J., Muir A. W., Palin R., Rees D. C., Zhang M. Q. A novel concept of reversing neuromuscular block: Chemical encapsulation of rocuronium bromide by a cyclodextrin-based synthetic host. Angew Chem Int Ed Engl. 2002;41(2):266–270. doi: 10.1002/1521-3773(20020118)41:2<265::AID-ANIE265>3.0.CO;2-Q. [DOI] [PubMed] [Google Scholar]
  • 276.Virués C., Zquez E. F. V., Inoue M. B., Inoue M. NMR studies of host guest complexes of anionic cyclophanes with dopamine and its analogues in aqueous media. J Inclusion Phenom Macrocyclic Chem. 2004;48(3–4):141–146. [Google Scholar]
  • 277.Yoon J., Kim S. K., Singh N. J., Kim K. S. Imidazolium receptors for the recognition of anions. Chem Soc Rev. 2006;35(4):355–360. doi: 10.1039/b513733k. [DOI] [PubMed] [Google Scholar]
  • 278.Baker M. V., Brown D. H., Heath C. H., Skelton B. W., White A. H., Williams C. C. Azolium-linked cyclophanes: Effects of structure, solvent, and counteranions on solution conformation behavior. J Org Chem. 2008;73(23):9340–9352. doi: 10.1021/jo801860d. [DOI] [PubMed] [Google Scholar]
  • 279.Baker M. V., Bosnich M. J., Brown D. H., Byrne L. T., Hesler V. J., Skelton B. W., White A. H., Williams C. C. Azolium-linked cyclophanes: A comprehensive examination of conformations by 1H NMR spectroscopy and structural studies. J Org Chem. 2004;69(22):7640–7652. doi: 10.1021/jo049097o. [DOI] [PubMed] [Google Scholar]
  • 280.Zhou C. H. Dissertation for the Doctoral Degree (in Chinese) Chengdu: Sichuan University; 1996. Design and synthesis of imidazolium cyclophanes and their biomimetic chemistry. [Google Scholar]
  • 281.Zuo Z., Tam Y. K., Diakur J., Wiebe L. I. Hydroxypropyl-beta- cyclodextrin-flutamide inclusion complex. II. Oral and intravenous pharmacokinetics of flutamide in the rat. J Pharm Pharm Sci. 2002;5(3):292–298. [PubMed] [Google Scholar]
  • 282.Bary A. R., Tucker I. G., Davies N. M. Considerations in the use of hydroxypropyl-beta-cyclodextrin in the formulation of aqueous ophthalmic solutions of hydrocortisone. Eur J Pharm Biopharm. 2000;50(2):: 237–244. doi: 10.1016/s0939-6411(00)00108-9. [DOI] [PubMed] [Google Scholar]

Articles from Science in China. Series B, Chemistry are provided here courtesy of Nature Publishing Group

RESOURCES